Compare Ginkgo Bioworks Holdings Inc (DNA) vs Sunrun Inc (RUN) Price & Performance

Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.

While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.

Sunrun (RUN) trades at $7.55, down 0.79% recently, with technical indicators showing bearish momentum despite strong analyst support. The company demonstrates solid profitability with 35.29% gross margins and has beaten earnings expectations for three consecutive quarters. Recent partnerships with Tesla and Voltus highlight strategic positioning in distributed energy, though negative operating cash flow and high debt levels present challenges.

The stock appears fundamentally undervalued with a P/E of 5.16 and P/S of 0.59, while analyst consensus targets $16.33 representing 116% upside potential. However, persistent negative cash flows, high interest expenses, and solar industry headwinds from borrowing costs create significant execution risks that could limit near-term performance despite the attractive valuation.